CytomX Therapeutics
Update in progressCTMX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
CytomX Therapeutics is an oncology-focused biopharmaceutical company that uses conditional activation platforms to create potent biologics for the tumor microenvironment. Its PROBODY technology aims to widen therapeutic windows for antibody–drug conjugates, T-cell engagers, and immune modulators. Lead assets include CX-904, CX-2051, CX-801, CX-2029, and BMS-986288, with collaborations with Amgen, Astellas, BMS, Regeneron, Moderna, and Merck. Founded 2008 in South San Francisco.
Company score
- Sentiment
- -0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.43
- Governance
- -0.18
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.17
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Sean A. McCarthy DPHIL
- Founded2008
- Employees69
- Websitewww.cytomx.com
Identifiers
- ISINUS23284F1057
- FIGIBBG001J472L3
- LEI5493004VW2FW0QLL3345
- CUSIP23284F105
- CIK0001501989